Enzymatic Lysis of Microbial Cells
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
RIPA Buffer Lysis Protocol
PROVOST & WALLERT RESEARCH Investigating the Biochemistry and Cellular Physiology of NHE1 EST. 1998 Whole Cell Lysate Preparation using RIPA Buffer – for membrane and soluble proteins RIPA Buffer (Radio-Immune Precipitation Assay) is used to lyse cultured cells to prepare protein extraction from cytoplasmic, membrane and nuclear proteins. Samples prepared with RIPA Buffer can easily be used with a BCA protein assay, western blot, immuno assays or other biochemical determintion. To maintain proteins in the state at time of lysis it is critical to keep cells on ice and only use ice cold buffer throughout to reduce protease, kinase, phosphatase or other enzymatic activity of lysates. T-25 flasks: 1) Remove old media and rinse cells with 2-3 ml of ice cold PBS. 2) Tilt flask 1-2 min on ice to drain residual PBS and remove by aspiration. 3) Add 0.5 ml of ice cold PBS and scrape cells. Transfer to labeled chilled microfuge tube. 4) Rinse cells with additional 1 ml of PBS and add to scraped cells. 5) Centrifuge at 2,500 x g for 5 min at 4oC. Decant supernate, keep pelleted cells. 6) Resuspend pellet in 0.25 ml of RIPA Buffer – use a pipet tip to suspend cells. 7) Lyse cells by sonication for 2, 30 second pulses (50% power) while on ice. 8) Shake mixture gently on ice for 15 min. 9) Centrifuge samples at ~14,000 x g for 15 min to pellet cell debris. Keep supernatant soln. 10) Perform BCA (Pierce) NOT Bradford/biorad protein assay. RIPA Buffer 50 mM Tris-HCl, pH 7.4, 150 mM sodium chloride, 1 mM ethylenediaminetetraacetic acid (EDTA), 1% NP-40 1% Sodium Deoxycholic acid, 0.1% sodium dodecylsulfate (SDS), 1 mM phenylmethylsulfonyl fluoride, (add fresh) Protease Inhibitors (add fresh - see manufacturer’s instructions) . -
Electrical Lysis: Dynamics Revisited and Advances in On-Chip Operation
Critical Reviews™ in Biomedical Engineering, 41(1):37–50 (2013) Electrical Lysis: Dynamics Revisited and Advances in On-chip Operation Bashir I. Morshed,1,* Maitham Shams,2 & Tofy Mussivand3 1Department of Electrical & Computer Engineering, University of Memphis, Memphis, TN 38152; 2Department of Elec- tronics, Carleton University, Ottawa, ON, Canada; 3Medical Devices Innovation Institute, University of Ottawa, Ottawa, ON, Canada * Address all correspondence to: Bashir I. Morshed, Ph.D., Assistant Professor, 204C Engineering Science Building, Department of Electrical & Computer Engineering, University of Memphis, Memphis, TN 38152; Tel.: 901-678-3650; Fax: 901-678-5469: [email protected]. ABSTRACT: Electrical lysis (EL) is the process of breaking the cell membrane to expose the internal contents under an applied high electric field. Lysis is an important phenomenon for cellular analysis, medical treatment, and biofoul- ing control. This paper aims to review, summarize, and analyze recent advancements on EL. Major databases includ- ing PubMed, Ei Engineering Village, IEEE Xplore, and Scholars Portal were searched using relevant keywords. More than 50 articles published in English since 1997 are cited in this article. EL has several key advantages compared to other lysis techniques such as chemical, mechanical, sonication, or laser, including rapid speed of operation, ability to control, miniaturization, low cost, and low power requirement. A variety of cell types have been investigated for including protoplasts, E. coli, yeasts, blood cells, and cancer cells. EL has been developed and applied for decon- tamination, cytology, genetics, single-cell analysis, cancer treatment, and other applications. On-chip EL is a promis- ing technology for multiplexed automated implementation of cell-sample preparation and processing with micro- or nanoliter reagents. -
The Bacteriophage Mu Lysis System--A New Mechanism of Host
BIOCELL Tech Science Press 2021 45(5): 1175-1186 The bacteriophage mu lysis system–A new mechanism of host lysis? SAIKAT SAMANTA1,#;ASHISH RANJAN SHARMA2,#;ABINIT SAHA1;MANOJ KUMAR SINGH1;ARPITA DAS1; MANOJIT BHATTACHARYA3;RUDRA PRASAD SAHA1,*;SANG-SOO LEE2,*;CHIRANJIB CHAKRABORTY1,* 1 Department of Biotechnology, School of Life Science & Biotechnology, Adamas University, Kolkata, 700126, India 2 Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, 24252, Korea 3 Department of Zoology, Fakir Mohan University, Balasore, 56020, India Key words: Bacteriophage Mu, Host cell lysis, Endolysin, Holin, Spanin Abstract: Bacteriophages are viruses that infect bacteria and can choose any one of the two alternative pathways for infection, i.e., lysis or lysogeny. Phage lysis is one of the conventional biological processes required to spread infection from one bacterium to another. Our analysis suggests that in the paradigm bacteriophage Mu, six proteins might be involved in host cell lysis. Mu has a broad host range, and Mu-like phages were found in both Gram-negative and Gram-positive bacteria. An analysis of the genomes of Mu and Mu-like phages could be useful in elucidating the lysis mechanism in this group of phages. A detailed review of the various mechanisms of phage lysis and different proteins associated with the process will help researchers understand the phage biology and their life cycle in different bacteria. The recent increase in the number of multidrug-resistant (MDR) strains of bacteria and the usual long-term nature of new drug development has encouraged scientists to look for alternative strategies like phage therapy and the discovery of new lysis mechanisms. -
Optimal Control of Innate Immune Response
OPTIMAL CONTROL APPLICATIONS AND METHODS Optim. Control Appl. Meth., 2002; 23: 91–104 (DOI: 10.1002/oca.704) Optimal control of innate immune response Robert F. Stengel*, Raffaele Ghigliazza, Nilesh Kulkarni and Olivier Laplace School of Engineering and Applied Science, Princeton University, Princeton, NJ 08544, U.S.A SUMMARY Treatment of a pathogenic disease process is interpreted as the optimal control of a dynamic system. Evolution of the disease is characterized by a non-linear, fourth-order ordinary differential equation that describes concentrations of pathogens, plasma cells, and antibodies, as well as a numerical indication of patient health. Without control, the dynamic model evidences sub-clinical or clinical decay, chronic stabilization, or unrestrained lethal growth of the pathogen, depending on the initial conditions for the infection. The dynamic equations are controlled by therapeutic agents that affect the rate of change of system variables. Control histories that minimize a quadratic cost function are generated by numerical optimization over a fixed time interval, given otherwise lethal initial conditions. Tradeoffs between cost function weighting of pathogens, organ health, and use of therapeutics are evaluated. Optimal control solutions that defeat the pathogen and preserve organ health are demonstrated for four different approaches to therapy. It is shown that control theory can point the way toward new protocols for treatment and remediation of human diseases. Copyright # 2002 John Wiley & Sons, Ltd. KEY WORDS: optimal control; biological modelling; bioinformatics; optimization INTRODUCTION Immune-system response to invasion by infectious microbes is a dynamic process in which potentially uncontrolled growth of the invader (or pathogen) is countered by various protective mechanisms. -
Targeting the Tryptophan Hydroxylase 2 Gene for Functional Analysis in Mice and Serotonergic Differentiation of Embryonic Stem Cells
TARGETING THE TRYPTOPHAN HYDROXYLASE 2 GENE FOR FUNCTIONAL ANALYSIS IN MICE AND SEROTONERGIC DIFFERENTIATION OF EMBRYONIC STEM CELLS Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by Dana Kikic, M.Sc. in Molecular biology and Physiology from Nis June, 2009 The doctorate studies were performed in the research group of Prof. Michael Bader Molecular Biology of Peptide Hormones at Max-Delbrück-Center for Molecular Medicine in Berlin, Buch Mai 2005 - September 2008. 1st Reviewer: Prof. Michael Bader 2nd Reviewer: Prof. Udo Heinemann date of defence: 13. August 2009 ACKNOWLEDGMENTS Herewith, I would like to acknowledge the persons who made this thesis possible and without whom my initiation in the world of basic science research would not have the spin it has now, neither would my scientific illiteracy get the chance to eradicate. I am expressing my very personal gratitude and recognition to: Prof. Michael Bader, for an inexhaustible guidance in all the matters arising during the course of scientific work, for an instinct in defining and following the intellectual challenge and for letting me following my own, for necessary financial support, for defining the borders of reasonable and unreasonable, for an invaluable time and patience, and an amazing efficiency in supporting, motivating, reading, correcting and shaping my scientific language during the last four years. Prof. Harald Saumweber and Prof. Udo Heinemann, for taking over the academic supervision of the thesis, and for breathing in it a life outside the laboratory walls and their personal signature. -
Functional Analysis of Chimeric Lysin Motif Domain Receptors Mediating Nod Factor-Induced Defense Signaling in Arabidopsis Thali
The Plant Journal (2014) 78, 56–69 doi: 10.1111/tpj.12450 Functional analysis of chimeric lysin motif domain receptors mediating Nod factor-induced defense signaling in Arabidopsis thaliana and chitin-induced nodulation signaling in Lotus japonicus Wei Wang1,2, Zhi-Ping Xie1,* and Christian Staehelin1,* 1State Key Laboratory of Biocontrol and Guangdong Key Laboratory of Plant Resources, School of Life Sciences, Sun Yat-sen University, East Campus, Guangzhou 510006, China, and 2Anhui Key Laboratory of Plant Genetics & Breeding, School of Life Sciences, Anhui Agricultural University, 130 Changjiang West Road, Hefei, Anhui 230036, China Received 12 October 2013; revised 11 January 2014; accepted 16 January 2014; published online 8 February 2014. *For correspondence (e-mails [email protected] or [email protected]). SUMMARY The expression of chimeric receptors in plants is a way to activate specific signaling pathways by corre- sponding signal molecules. Defense signaling induced by chitin from pathogens and nodulation signaling of legumes induced by rhizobial Nod factors (NFs) depend on receptors with extracellular lysin motif (LysM) domains. Here, we constructed chimeras by replacing the ectodomain of chitin elicitor receptor kinase 1 (AtCERK1) of Arabidopsis thaliana with ectodomains of NF receptors of Lotus japonicus (LjNFR1 and LjNFR5). The hybrid constructs, named LjNFR1–AtCERK1 and LjNFR5–AtCERK1, were expressed in cerk1-2, an A. thaliana CERK1 mutant lacking chitin-induced defense signaling. When treated with NFs from Rhizobi- um sp. NGR234, cerk1-2 expressing both chimeras accumulated reactive oxygen species, expressed chitin- responsive defense genes and showed increased resistance to Fusarium oxysporum. In contrast, expression of a single chimera showed no effects. -
Structural Engineering of a Phage Lysin That Targets Gram-Negative Pathogens
Structural engineering of a phage lysin that targets Gram-negative pathogens Petra Lukacika, Travis J. Barnarda, Paul W. Kellerb, Kaveri S. Chaturvedic, Nadir Seddikia,JamesW.Fairmana, Nicholas Noinaja, Tara L. Kirbya, Jeffrey P. Hendersonc, Alasdair C. Stevenb, B. Joseph Hinnebuschd, and Susan K. Buchanana,1 aLaboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892; bLaboratory of Structural Biology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda,MD 20892; cCenter for Women’s Infectious Diseases Research, Washington University School of Medicine, St. Louis, MO 63110; and dLaboratory of Zoonotic Pathogens, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840 Edited by* Brian W. Matthews, University of Oregon, Eugene, OR, and approved April 18, 2012 (received for review February 27, 2012) Bacterial pathogens are becoming increasingly resistant to antibio- ∼10 kb plasmid called pPCP1 (7). Pla facilitates invasion in bu- tics. As an alternative therapeutic strategy, phage therapy reagents bonic plague and, as such, is an important virulence factor (8, 9). containing purified viral lysins have been developed against Gram- When strains lose the pPCP1 plasmid, they are killed by pesticin positive organisms but not against Gram-negative organisms due thus ensuring maximal virulence in the bacterial population. to the inability of these types of drugs to cross the bacterial outer Bacteriocins belong to two classes. Type A bacteriocins depend membrane. We solved the crystal structures of a Yersinia pestis on the Tolsystem to traverse the outer membrane, whereas type B outer membrane transporter called FyuA and a bacterial toxin bacteriocins require the Ton system. -
Development of Phage Lysins As Novel Therapeutics: a Historical Perspective
viruses Essay Development of Phage Lysins as Novel Therapeutics: A Historical Perspective Vincent A. Fischetti ID Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, 1230 York Avenue, New York, NY 10065, USA; [email protected] Received: 10 May 2018; Accepted: 5 June 2018; Published: 7 June 2018 Abstract: Bacteriophage lysins and related bacteriolytic enzymes are now considered among the top antibiotic alternatives for solving the mounting resistance problem. Over the past 17 years, lysins have been widely developed against Gram-positive and recently Gram-negative pathogens, and successfully tested in a variety of animal models to demonstrate their efficacy. A lysin (CF-301) directed to methicillin resistant Staphylococcus aureus (MRSA) has effectively completed phase 1 human clinical trials, showing safety in this novel therapeutic class. To validate efficacy, CF-301 is currently the first lysin to enter phase 2 human trials to treat hospitalized patients with MRSA bacteremia or endocarditis. If successful, it could be the defining moment leading to the acceptance of lysins as an alternative to small molecule antibiotics. This article is a detailed account of events leading to the first therapeutic use and ultimate development of phage-encoded lysins as novel anti-infectives. Keywords: phage; lysins; endolysins; lytic enzymes; discovery; therapeutic; antibiotic resistance; alternative to antibiotics 1. Preface Since 2001, when our first paper was published describing the in vivo use of phage enzymes as potential therapeutics, I have been asked many times: “How did you think of doing this?” This article is a detailed answer to that question. I certainly was not the only person in the world working on phage lysins at the time; however, I was one of the few working with a highly-active lysin against Gram-positive bacteria. -
RBC Lysis Buffer Product Insert Product # 21201 (90 Ml) Product #21205 (500 Ml)
3430 Schmon Parkway Thorold, ON, Canada L2V 4Y6 Phone: 866-667-4362 • (905) 227-8848 Fax: (905) 227-1061 Email: [email protected] RBC Lysis Buffer Product Insert Product # 21201 (90 mL) Product #21205 (500 mL) Norgen’s RBC Lysis Buffer is designed for the differential lysis of red blood cells present in whole blood samples. The removal of red blood cells from whole blood is often desirable, particularly during the study of leukocyte DNA, proteins or RNA. Abundant proteins (including albumin) and RNAs (including globin mRNA) that are present in red blood cells and may interfere with downstream applications such as expression analysis are effectively removed during this process. For the procedure, whole blood samples are first collected in the presence of anticoagulants. The red blood cells are then removed through lysis using the RBC Lysis Buffer, and the leukocytes which remain can then be recovered by centrifugation. Genomic DNA, proteins or RNA can then be isolated from the purified leukocytes, as Norgen’s RBC Lysis Buffer is RNAase and DNase free. Product Components Component Product # 21201 Product # 2120 5 RBC Lysis Buffer 90 mL 500 mL Product Insert 1 1 Storage Conditions and Product Stability The RBC Lysis Buffer should be stored at 4°C. This reagent should remain stable for at least 1 year in its unopened container. Precautions and Disclaimers This reagent is designed for research purposes only. It is not intended for human or diagnostic use. Ensure that a suitable lab coat, disposable gloves and protective goggles are worn when working with chemicals. For more information, please consult the appropriate Material Safety Data Sheets (MSDSs). -
Antibody-Complement Cell Lysis LORNE A
INFECTION AND IMMUNITY, Nov. 1975, p. 958-963 Vol. 12, No. 5 Copyright © 1975 American Society for Microbiology Printed in USA. Defense Mechanisms Against Bovine Herpesvirus: Relationship of Virus-Host Cell Events to Susceptibility to Antibody-Complement Cell Lysis LORNE A. BABIUK, RICHARD C. WARDLEY, AND BARRY T. ROUSE* Department of Veterinary Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada Received for publication 30 June 1975 The interaction of infectious bovine rhinotracheitis virus and susceptible host cells was examined to determine whether an infected cell could be destroyed by humoral immune mechanisms before or after the transmission of virus to susceptible adjacent cells. Viral antigens were detectable on cell membranes at 6 h postinfection, but cells were not susceptible to antibody-complement lysis until 10 h postinfection. Intracellular infectious virus was also detectable at 10 h postinfection, and transmission to adjacent cells by the intracellular route began at this time. Extracellular virus was not detectable until 12 to 13 h postinfection. By the continual addition of antibody and complement, virus dissemination could be reduced more than 50-fold. These results support the hypothesis that the humoral immune mechanism may be involved in the recovery from herpesvi- rus infections. Most herpesvirus infections are characterized seminated to susceptible adjacent cells. Subse- by recurrent infections, with the virus persist- quent communications will examine this ques- ing in the body almost indefinitely. In infec- tion with respect to other components of the tious bovine rhinotracheitis (IBR) infection of immune response. cattle, usually there is only a single episode of symptomatic infection; nevertheless, the virus MATERIALS AND METHODS does persist and can be reactivated (4, 15, 16). -
Design, Overproduction and Purification of the Chimeric Phage
processes Article Design, Overproduction and Purification of the Chimeric Phage Lysin MLTphg Fighting against Staphylococcus aureus 1, 1, 1, 1, 1 1 Feng Wang y , Xiaohang Liu y, Zhengyu Deng y, Yao Zhang y, Xinyu Ji , Yan Xiong and Lianbing Lin 1,2,* 1 Faculty of Life Science and Technology, Kunming University of Science and Technology, 727 South Jingming Road, Kunming 650500, China; [email protected] (F.W.); [email protected] (X.L.); [email protected] (Z.D.); [email protected] (Y.Z.); [email protected] (X.J.); [email protected] (Y.X.) 2 Engineering Research Center for Replacement Technology of Feed Antibiotics of Yunnan College, 727 South Jingming Road, Kunming 650500, China * Correspondence: [email protected]; Tel.: +86-139-8768-1986; Fax: +86-0871-65920570 These authors contributed equally to this work. y Received: 13 October 2020; Accepted: 24 November 2020; Published: 1 December 2020 Abstract: With the increasing spread of multidrug-resistant bacterial pathogens, it is of great importance to develop alternatives to conventional antibiotics. Here, we report the generation of a chimeric phage lysin, MLTphg, which was assembled by joining the lysins derived from Meiothermus bacteriophage MMP7 and Thermus bacteriophage TSP4 with a flexible linker via chimeolysin engineering. As a potential antimicrobial agent, MLTphg can be obtained by overproduction in Escherichia coli BL21(DE3) cells and the following Ni-affinity chromatography. Finally, we recovered about 40 1.9 mg of MLTphg from 1 L of the host E. coli BL21(DE3) culture. The purified MLTphg ± showed peak activity against Staphylococcus aureus ATCC6538 between 35 and 40 ◦C, and maintained approximately 44.5 2.1% activity at room temperature (25 C). -
A Crude Extract Preparation and Optimization from a Genomically Engineered Escherichia Coli for the Cell-Free Protein Synthesis System: Practical Laboratory Guideline
Protocol A Crude Extract Preparation and Optimization from a Genomically Engineered Escherichia coli for the Cell-Free Protein Synthesis System: Practical Laboratory Guideline 1, 1, 1 1,2, Jeehye Kim y , Caroline E. Copeland y, Sahana R. Padumane and Yong-Chan Kwon * 1 Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, LA 70803, USA 2 Louisiana State University Agricultural Center, Baton Rouge, LA 70803, USA * Correspondence: [email protected]; Tel: +1-225-578-4325 These authors contributed equally to this work. y Received: 2 July 2019; Accepted: 7 August 2019; Published: 9 August 2019 Abstract: With the advancement of synthetic biology, the cell-free protein synthesis (CFPS) system has been receiving the spotlight as a versatile toolkit for engineering natural and unnatural biological systems. The CFPS system reassembles the materials necessary for transcription and translation and recreates the in vitro protein synthesis environment by escaping a physical living boundary. The cell extract plays an essential role in this in vitro format. Here, we propose a practical protocol and method for Escherichia coli-derived cell extract preparation and optimization, which can be easily applied to both commercially available and genomically engineered E. coli strains. The protocol includes: (1) The preparation step for cell growth and harvest, (2) the thorough step-by-step procedures for E. coli cell extract preparation including the cell wash and lysis, centrifugation, runoff reaction, and dialysis, (3) the preparation for the CFPS reaction components and, (4) the quantification of cell extract and cell-free synthesized protein. We anticipate that the protocol in this research will provide a simple preparation and optimization procedure of a highly active E.